生产企业：Praxis Precision Medicines
PRAX-562 (relutrigine) is an investigational precision medicine developed by Praxis Precision Medicines for genetically defined developmental and epileptic encephalopathies (DEEs). It is being evaluated as a targeted therapy for SCN2A-DEE and SCN8A-DEE. In March 2026, the FDA accepted its New Drug Application for Priority Review with a PDUFA target action date of September 27, 2026. DelveInsight market analysis projects relutrigine to be among the top three emerging therapies in the DEE market by 2036, following zorevunersen and bexicaserin.
PRAX-562 (relutrigine) is an investigational precision medicine developed by Praxis Precision Medicines for genetically defined developmental and epileptic encephalopathies (DEEs). It is being evaluated as a targeted therapy for SCN2A-DEE and SCN8A-DEE. In March 2026, the FDA accepted its New Drug Application for Priority Review with a PDUFA target action date of September 27, 2026. DelveInsight market analysis projects relutrigine to be among the top three emerging therapies in the DEE market by 2036, following zorevunersen and bexicaserin.
Under investigation for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). In March 2026, the FDA accepted the New Drug Application for Priority Review with a PDUFA target action date of September 27, 2026.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
